Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.

Details

Serval ID
serval:BIB_8DFFA0A50DF3
Type
Article: article from journal or magazin.
Publication sub-type
Minutes: analyse of a published work.
Collection
Publications
Title
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.
Journal
Journal of Immunotherapy
Author(s)
Lotze M.T., Wang E., Marincola F.M., Hanna N., Bugelski P.J., Burns C.A., Coukos G., Damle N., Godfrey T.E., Howell W.M., Perricone M.A., Petricoin E.F., Sauter G., Scheibenbogen C., Shivers S.C., Taylor D.L., Weinstein J.N., Whiteside T.L.
Working group(s)
Panelli M.C.
ISSN
1524-9557 (Print)
ISSN-L
1524-9557
Publication state
Published
Issued date
2005
Volume
28
Number
2
Pages
79-119
Language
english
Notes
Publication types: CongressesPublication Status: ppublish. Report from the International Society for Biological Therapy of Cancer
Abstract
The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor. We distinguish this from immunologic monitoring in the sense that it is primarily a measure of the tumor burden as opposed to the immune response to it. Recommendations for intensive investigation and targeted funding to enable such strategies were developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies.
Keywords
Alternative Splicing, Biological Markers, Clinical Trials as Topic, Computational Biology/methods, DNA/metabolism, DNA Methylation, Flow Cytometry, Gene Expression Profiling/methods, Humans, Immunohistochemistry, Internet, Lymph Nodes/pathology, Monitoring, Immunologic, Necrosis, Neoplasms/blood, Neoplasms/diagnosis, Oligonucleotide Array Sequence Analysis, Polymorphism, Genetic, Polymorphism, Single Nucleotide, Protein Binding, Proteomics, RNA, Messenger/metabolism, Reverse Transcriptase Polymerase Chain Reaction, Tissue Distribution, Tumor Markers, Biological
Pubmed
Create date
14/10/2014 11:42
Last modification date
20/08/2019 14:51
Usage data